2,117 material Form 8-K filings that 1,813 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,046 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Sypris Solutions disclosed that Curtis S. Petrie, its Vice President of Administration, began a medical leave of absence effective November 3, 2026. The company did not state how long the leave will last. The filing reports an administrative personnel change and does not address financial results or operations.
Curtis S. Petrie, Vice President of Administration, began medical leave effective November 3, 2026
The duration of the leave has not yet been determined
The filing does not mention a replacement or interim arrangement
RPM presented its MAP 2030 operating improvement program at an Investor Day in Cherry Hill, New Jersey, on November 9, 2026. The company set fiscal 2030 targets of $10 billion in revenue, $2 billion in adjusted EBITDA, a 20% adjusted EBITDA margin and a $30 billion market capitalization, up from fiscal 2026 net sales of $7,863 million and adjusted EBITDA of $1,228 million (15.6% margin).
Fiscal 2026 net sales were $7,863 million, with adjusted EBITDA of $1,228 million, a 15.6% margin.
Fiscal 2030 targets include $10 billion in revenue and $2 billion in adjusted EBITDA, a 20% margin.
The presentation is attached as Exhibit 99.1, and the Investor Day event will be recorded with a replay on the company website.
The company did not provide a reconciliation of its fiscal 2030 adjusted EBITDA target to GAAP, citing terms outside its control.
Oppenheimer Holdings subsidiary Viner Finance entered into a lease on November 5, 2026, for about 221,339 rentable square feet at 32 Old Slip in Lower Manhattan, to serve as the firm's principal New York City offices. Fixed annual rent is approximately $13.3 million for the first five years after rent commencement, rising in later periods, and the company expects significant additional capital spending for furniture, equipment and technology tied to the relocation.
Lease covers about 221,339 rentable square feet with an initial term of approximately 15.5 years.
Rent commencement is the later of six months after final delivery of the Premises and July 1, 2028; fixed rent is about $13.3 million a year for the first five years, $14.4 million for the next five, and $15.5 million thereafter.
Viner has an option to terminate at the tenth anniversary of rent commencement for a termination fee of a maximum aggregate of approximately $24 million.
Oppenheimer's press release says phased move-in is targeted to begin in the first quarter of 2028.
United States Antimony Corporation announced that it will release its third quarter 2026 financial and operating results and hold a conference call and webcast on Thursday, November 12, 2026, at 4:15 p.m. Eastern time. The filing only sets the date and time and does not include any results, so it gives shareholders no new financial figures.
Third quarter 2026 results and nine-month results to be released after U.S. markets close on November 12, 2026
Conference call and webcast begin at 4:15 p.m. Eastern time on November 12, 2026
Press release announcing the date was issued November 9, 2026 and filed as Exhibit 99.1
Oncolytics Biotech announced translational data from a Phase 1b/2 trial in relapsed/refractory multiple myeloma patients, showing that pelareorep can engage the immune system and combine with standard-of-care therapies. The data will be presented as a poster at the 68th American Society of Hematology Annual Meeting and Exposition, and the filing includes no financial results, guidance, or new trial efficacy figures.
Poster presentation (Abstract 2183) scheduled for Saturday, December 12, 2026 at the ASH Annual Meeting
Phase 1b/2 trial compared bortezomib, dexamethasone and pembrolizumab (Cohort 1) with pelareorep plus those drugs (Cohort 2)
Patients had a median of four prior lines of therapy, with a range of three to eleven
Patients who responded to treatment showed greater expansion of CD8 effector memory T cells than non-responders
Crexendo, Inc. posted an investor presentation to its website on November 9, 2026, and attached it as Exhibit 99.1 to this Form 8-K. The filing is furnished under Regulation FD and does not state any financial results, guidance, or other new figures in its text.
Investor presentation posted to www.crexendo.com/investor on November 9, 2026
Presentation attached as Exhibit 99.1, dated November 2026
Filing text contains no revenue, profit, or guidance figures; the exhibit text provided is blank apart from line numbers
Exascale Labs countersigned a $9.04 million firm purchase order for 16 Intel BHS 10U GPU servers with NVIDIA HGX B300 GPUs from Compal Electronics. The filing also describes a framework that would let the company buy up to 128 servers in total, but it places no minimum purchase obligation on the company, and the second order has not been placed. The filing does not describe financial results, and it is not clear how the servers will be funded or used.
Purchase covers 16 servers at $565,000 each, for an aggregate price of $9,040,000 excluding taxes
Down payment of $1,808,000 (20%) due within five business days of Compal's written order confirmation; remaining $7,232,000 (80%) due before shipment
Framework allows purchases of up to 128 servers through March 31, 2027, with no minimum commitment; no order has been placed under the second framework agreement
Company agreed to a storage arrangement and a three-year warranty from Compal; Compal and the company are described as unaffiliated
Werewolf Therapeutics released early clinical data for its two INDUKINE candidates, WTX-124 and WTX-330, presented at the Society for Immunotherapy of Cancer's 2026 Annual Meeting. The company said it has aligned with the FDA on an 18 mg IV Q2W recommended Phase 2 dose for WTX-124 and that WTX-330 was well tolerated. The filing contains no financial results, and the data come from small early-stage trials, so shareholders will mainly weigh the programs' future development prospects.
WTX-124 recommended Phase 2 dose set at 18 mg IV Q2W, aligned with the FDA, for monotherapy and combination with pembrolizumab
WTX-124 monotherapy produced one durable confirmed complete response in a patient with ICI-resistant cutaneous squamous cell carcinoma, ongoing for approximately three years
WTX-330 data from 24 patients showed a confirmed partial response in a patient with gallbladder cancer, per the filing
TMC USA, a subsidiary of TMC the metals Co Inc., received a letter from NOAA stating it expects to notify TMC USA of its final determination on certification of its consolidated application for an exploration license and commercial recovery permit by mid-December 2026. The filing notes the timing is an estimate, DSHMRA sets no mandatory deadline, and certification is an intermediate step that is not an approval or issuance of a license or permit.
NOAA letter received by TMC USA on November 3, 2026
NOAA expects to notify TMC USA of its final determination on certification by mid-December 2026
Application covers an exploration license and a commercial recovery permit under DSHMRA
Filing states certification does not constitute approval or issuance of a license or permit
Inflection Point Acquisition Corp. VI filed an 8-K furnishing a Quantum Space press release announcing a Virtual Analyst Day on November 9, 2026, from 10:00 a.m. to 11:45 a.m. Eastern Time. The event is a Quantum Space investor presentation tied to the pending business combination, which the filing says has not yet closed and includes no new financial results.
Quantum Space Virtual Analyst Day held November 9, 2026, 10:00 a.m. to 11:45 a.m. ET, with Q&A.
Presenters include CEO Jim Bridenstine, President Kerry Wisnosky and CFO Adarsh Parekh.
Business combination agreement with Inflection Point was signed June 8, 2026; combined company expected to list on the NYSE as QSPC.
Registration Statement on Form S-4 was declared effective October 28, 2026, and the proxy statement/prospectus was mailed to shareholders.
Century Communities' board elected James Francescon, age 37, as President effective January 1, 2027, succeeding Robert J. Francescon in that role. Robert J. Francescon remains Chief Executive Officer and becomes the sole principal executive officer, while Executive Chairman Dale Francescon no longer shares that title. The filing discloses a $750,000 base salary and a promotional award of 35,008 restricted stock units for James Francescon, and it reports no financial results.
Base salary of $750,000 and a target annual bonus of at least 200% of base salary, effective January 1, 2027.
Promotional RSU award of 35,008 shares, granted November 4, 2026, vesting in three equal annual installments.
Robert J. Francescon becomes sole principal executive officer; James Francescon is his son and Dale Francescon's nephew.
Company announced the promotion in a press release dated November 9, 2026, as part of its succession planning.
SM Energy appointed George Green as Senior Vice President and Chief Legal Officer and Corporate Secretary, effective November 9, 2026. James Lebeck, who previously held the general counsel and corporate secretary roles, will remain as Executive Vice President and Chief Corporate Development Officer. The change is an executive reshuffle in the legal function and does not include any financial results or guidance.
George Green appointed Senior Vice President – Chief Legal Officer and Corporate Secretary, effective November 9, 2026
Green was General Counsel of PerkinElmer from June 2023 and previously Group Vice President and General Counsel at DCP Midstream from 2021 to 2023
James Lebeck will continue as Executive Vice President – Chief Corporate Development Officer
Coursera's board adopted a limited-duration stockholder rights plan, effective immediately, in response to a stockholder that its recent filings show owns about 14.7% of the common stock. The plan is designed to trigger if any person or group acquires 15% or more without board approval, which would dilute that holder's stake and could deter open-market accumulation.
The board declared a dividend of one preferred share purchase right per common share, payable November 19, 2026 to holders of record on that date.
Each right allows purchase of one one-thousandth of a preferred share for $19.50, becoming exercisable only after a person or group acquires 15% or more.
The rights expire November 7, 2027, and the board may redeem them for $0.01 per right before any person becomes an acquiring person.
The Certificate of Designations was filed with the Delaware Secretary of State on November 9, 2026.
Axogen furnished a corporate investor presentation dated November 9, 2026, on its prostate nerve reconstruction opportunity, which it posted to its website and may use in talks with analysts and investors. The filing contains no earnings, guidance, or deal terms, so it gives shareholders a view of management's market case rather than new financial results.
The presentation, titled Prostate Nerve Reconstruction Investor Event, is furnished as Exhibit 99.1 and dated November 9, 2026.
The company estimates a total addressable market of $754 million, based on about 110,000 cases per year at a weighted average selling price of about $7,000 per procedure.
Clinical data cited include more than 220 patients reconstructed with Avance at six months, with about 80% reporting better than expected erectile function.
Warner Music Group's Board of Directors declared a regular quarterly cash dividend of $0.20 per share on its Class A and Class B Common Stock. The dividend is payable December 1, 2026, to holders of record at the close of business on November 20, 2026. The filing describes a routine dividend declaration and does not report financial results.
Regular quarterly cash dividend of $0.20 per share on Class A and Class B Common Stock
Payable December 1, 2026
Stockholders of record as of the close of business on November 20, 2026
Bitmine Immersion Technologies announced in a November 9, 2026 press release that, as of November 8, 2026, its crypto, cash and marketable securities holdings totaled $14.3 billion, including 6,070,092 ETH. The update is a holdings disclosure rather than an earnings report, and it includes no revenue, profit or guidance figures.
ETH holdings: 6,070,092 tokens at $2,234 per ETH, about 4.97% of the 122.2 million ETH supply
Total cash and marketable securities of $475 million, plus a $180 million stake in Beast Industries and a $75 million stake in Eightco Holdings
Projected annualized staking rewards of $359 million at full staking, versus $309 million on 5.2 million staked ETH, based on a 2.65% trailing 7-day staking yield
Faeth Therapeutics filed a November 9, 2026 corporate presentation with topline results from its single-arm Phase 2 PIK-201 trial of PIKTOR plus paclitaxel in advanced endometrial cancer. The filing says the results are preliminary and that PIKTOR is investigational and not approved, so the data does not yet establish a commercial outlook for shareholders.
Confirmed objective response rate of 33% (12 of 36 efficacy-evaluable patients), with a 10.30.26 efficacy data cut
Preliminary median progression-free survival of 7.4 months (95% CI 5.3, not reached) across 42 treated patients
27 of 42 patients (64%) had a grade 3 or higher treatment-related adverse event, per the 10.23.26 safety data cut
Innovative Industrial Properties amended its equity distribution agreements to add its 9.25% Series B Cumulative Redeemable Preferred Stock to its at-the-market offering program, alongside common stock and 9.00% Series A Preferred Stock. About $336.9 million of the program's $500 million capacity remained available as of the filing date, which gives the company a path to issue more shares that could dilute existing holders.
Program covers common stock, Series A Preferred Stock and Series B Preferred Stock, with aggregate offering price of up to $500 million
Approximately $336.9 million remained available for sale under the ATM Prospectus Supplement dated November 9, 2026
Amendments were entered into November 9, 2026 with BTIG, Piper Sandler, Roth Capital, Stifel, A.G.P./Alliance Global Partners and Huntington Securities
SS&C Technologies completed a private offering of $1.2 billion of 2.75% convertible senior notes due December 1, 2031, including a $150 million option exercised in full by the initial purchasers. The company plans to use the proceeds for capped call transactions, share repurchases of about $100 million, and redeeming its $2.0 billion of 5.500% Senior Notes due 2027, which adds debt and creates potential dilution if the notes convert.
Notes issued November 6, 2026 under an indenture with Wilmington Trust, National Association, as trustee, bearing interest at 2.75% payable June 1 and December 1.
Initial conversion price of about $99.46 per share, a premium of about 25.0% over the $79.57 closing price on November 4, 2026.
Proceeds planned for about $99 million capped call cost, about $100 million of share repurchases (about 1.3 million shares), and redemption of the $2,000.0 million 2027 Senior Notes.
Company may not redeem the notes before December 5, 2029, except in a cleanup redemption.
Sonoco said CEO R. Howard Coker will retire as director, president and chief executive officer effective December 31, 2026. The board named Ernest D. Haynes III, the company's president of Global Consumer Packaging, to succeed him as CEO and as a director on that date.
Coker's retirement is effective December 31, 2026; the board accepted his notice dated November 6, 2026.
Haynes, who joined Sonoco in 1997, has an annual base salary of $1,100,004 and a bonus target of 120% of salary.
CFO Paul Joachimczyk received a $1,500,000 restricted stock unit retention award that cliff vests on the second anniversary of the grant date.
Sonoco leadership, including Coker, Haynes and Joachimczyk, will present at an R.W. Baird conference webcast on November 10, 2026, starting 7:20 a.m. Central Time.
Aptevo Therapeutics reported on November 9, 2026 that it presented new preclinical data from its next-generation multispecific platform at the SITC 2026 Annual Meeting on November 7, 2026. The lab results cover APVO451, APVO452 and APVO711, which the company says showed tumor-cell killing and immune activation under conditions that suppress immune responses. The filing contains no financial results, and the data are early-stage, so the update does not change reported financials.
Presentation made on November 7, 2026 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
APVO451 and APVO452 showed tumor-cell killing and T-cell activation under immunosuppressive conditions in preclinical studies.
APVO711 combined CD40 activation with PD-L1 checkpoint blockade in preclinical findings.
APVO451 and APVO452 are expected to advance into IND-enabling studies in 2027.
Newell Brands expanded its board from eight to nine members and elected William "Bill" Newlands as a director, effective January 1, 2027. Newlands previously served as President and CEO of Constellation Brands from 2019 to April 2026, and the filing says his experience in consumer brand strategy and capital allocation will be valuable to the company.
Board size increases from eight to nine members; Newlands' election takes effect January 1, 2027.
Newlands will serve on the Audit Committee and the Compensation and Human Capital Committee from January 1, 2027.
Newlands will receive the same compensation as the company's other non-employee directors, per the March 26, 2026 proxy statement.
Filing states there are no arrangements under which he was selected and no reportable related-party transactions.
Vistagen reported constructive FDA feedback from a Type C meeting on registrational paths for its lead product candidate, fasedienol, in social anxiety disorder. The company plans to use interim assessments, submit a revised protocol, and focus development on the general SAD population rather than acute treatment alone.
FDA gave constructive feedback on using the Liebowitz Social Anxiety Scale as the primary endpoint in a future Phase 3 study.
Vistagen plans to add interim assessments using eDiaries and qualitative patient surveys and to submit a revised protocol to the FDA.
The company plans to pursue fasedienol for overall, not only acute, treatment of SAD, and cited the FDA's recognition of its reported safety profile.
The filing contains no financial results, and the company states that future FDA feedback may not lead to a successful registrational pathway.
Empery Digital said on November 9, 2026 that it and Hunt Properties continue lease negotiations for the Midwest AI data center facility and expect to execute a lease in the near term. The definitive agreement to purchase the property has been amended and extended, and the company repurchased 155,040 shares in the week ended November 6, 2026, leaving approximately $49 million under its $200 million buyback authorization.
No lease has been executed yet; the company expects to execute one in the near term
Purchase agreement for the Midwest facility amended and extended while lease talks continue
Repurchased 155,040 shares in the week ended November 6, 2026 at an average of $2.36 per share
Aggregate repurchases reached 26,686,348 shares; about $49 million remains under the $200 million program
OneMedNet said year-to-date bookings reached approximately $18.76 million as of November 6, 2026, with $1.388 million converted to revenue through September 30, 2026. The company also reported that contracted demand is nearly 14 times its full-year 2025 bookings and that roughly half of its 2026 contracts come from new customers, while providing fourth-quarter 2026 guidance without figures in the filing text.
Year-to-date bookings: approximately $18.76 million as of November 6, 2026
Revenue converted from bookings: $1.388 million through September 30, 2026
Contracted demand is nearly 14 times full-year 2025 bookings
Roughly half of 2026 contracts are from new customers
Super League Enterprise disclosed that from November 4 through November 9, 2026, it purchased sixteen Bitcoin at an average price of approximately $76,892.32 per Bitcoin. The company said the purchases are part of its exploration of Bitcoin as a treasury asset alongside cash and cash equivalents. The filing is limited to this purchase and does not report financial results or guidance.
Purchased 16 Bitcoin between November 4, 2026 and November 9, 2026
Average purchase price of approximately $76,892.32 per Bitcoin
Company describes the buys as part of exploring Bitcoin as a treasury asset alongside cash and cash equivalents
DeFi Development Corp. (DFDV) reported in a Form 8-K that its SOL and SOL equivalent holdings rose by 8,881 between November 2 and November 6, 2026, to 2,609,829, up from 2,600,948 as of October 30. The company said it expects treasury SOL to be deployed through its staking, validator and onchain treasury infrastructure, subject to market conditions and risk management. The filing is a routine holdings update that includes no earnings or financial results.
SOL and SOL equivalents rose from 2,600,948 on October 30, 2026 to 2,609,829 on November 6, 2026.
The November 9, 2026 press release says this is the ninth consecutive week of SOL purchases, starting September 14, 2026.
The company's Variable Rate Series C Perpetual Preferred Stock (CHAD) carries a 14.00% annualized dividend rate on a $10.00 stated amount, or $1.40 per share annually.
The company's risk factors note that SOL price declines could cause losses and that CHAD dividends are payable only when declared.
LKQ Corporation said Salvatore A. Abbate will become President and Chief Executive Officer and join the Board effective November 9, 2026, earlier than the previously announced December 15, 2026 start date. The change ends the interim Office of the CEO led by Chairman John Mendel and Audit Committee Chair Sue Gove, which had overseen operations since October 23, 2026.
Abbate's start date moved from December 15, 2026 to November 9, 2026
Abbate becomes principal executive officer for SEC rules on November 9, 2026
Interim Office of the CEO, Mendel and Gove, which oversaw operations since October 23, concludes
Chairman Mendel said the Board has full confidence in Abbate
Jasper Therapeutics announced the results of its offer to purchase all outstanding warrants issued in its September 18, 2025 underwritten public offering, at $0.324 in cash per warrant, which expired on November 7, 2026. A total of 8,510,658 warrants were properly tendered, about 68.94% of the outstanding warrants, and the company expects to pay $2,757,453.19 in cash for them.
8,510,658 warrants were properly tendered and not withdrawn, about 68.94% of outstanding warrants.
Offer price was $0.324 in cash per warrant, without interest; the offer expired at 12:00 a.m. Eastern Time on November 7, 2026.
The company expects to pay an aggregate of $2,757,453.19 in cash, to be made promptly.
The offer was described in a Schedule TO originally filed with the SEC on October 7, 2026.
The merger between Mentari Therapeutics and InMed Pharmaceuticals closed on November 9, 2026, and the combined company now trades on the Nasdaq Capital Market as MTRI under the name Mentari Therapeutics, Inc. The closing included private placements with about $490 million in gross proceeds, which the company says provide runway into 2029, and the filing puts outstanding shares at about 58.3 million. The filing contains no revenue, profit, or guidance figures, so the financial effect on shareholders is defined mainly by the new capital and share count.
Private financings totaled about $490 million in gross proceeds, led by Fairmount, including conversion of $50.0 million of previously issued convertible notes plus accrued interest.
About 58.3 million shares of common stock and equivalents are outstanding after the reverse stock split, financings, and merger.
Shares began trading on Nasdaq Capital Market under the ticker MTRI on November 9, 2026.
Todd Shegog joined the Board and will chair the Audit Committee.
Evolv Technologies named Jason Blessing, age 55, as an independent director effective November 6, 2026, filling a Class III seat until the 2027 annual meeting. He also joins the Audit Committee and the Nominating and Corporate Governance Committee, and the board determined he meets audit committee independence requirements and qualifies as an audit committee financial expert.
Appointed effective November 6, 2026, to serve as a Class III director until the 2027 annual meeting of stockholders
Joins the Audit Committee and the Nominating and Corporate Governance Committee
Previously served as President and CEO of Model N, Inc. from May 2018 to September 2024, and as a Model N director until August 2026
Will receive compensation as a non-employee director under the company's Non-Employee Director Compensation Policy
CNH Industrial agreed to form a joint venture with Kobelco Construction Machinery by selling a 70% interest in its Construction Equipment business for $700 million in cash, based on an agreed enterprise value of $1 billion. CNH will keep a 30% stake and says it expects to use the net cash proceeds to reduce debt, but the deal requires regulatory approvals and is expected to close by the end of 2027.
Buyers pay $700 million in cash for 70% of the business, valued at an enterprise value of $1 billion, subject to adjustments
CNH retains a 30% interest in the joint venture, with a three-year lock-up period for each party
Closing is expected by the end of 2027; either party may terminate if closing has not occurred by March 30, 2028
CNH said it will report its 2026 third quarter earnings in a separate announcement the same day
Profound Medical Corp. said its management will take part in the Stifel 2026 Healthcare Conference in New York City on Thursday, November 12, 2026. The filing is a routine event announcement that furnishes a press release and contains no financial results, guidance, or other new business information.
President Richard Fabian is scheduled to present at 8:40 a.m. Eastern Time on November 12, 2026.
The presentation will be broadcast live and archived on the company's website.
CEO Arun Menawat and CFO Matthew Sobczyk will join Fabian for one-on-one investor meetings during the conference.
SiriusXM announced that Board director Anjali Sud, current CEO of Tubi, will become Chief Executive Officer on January 1, 2027, succeeding Jennifer C. Witz, who steps down as CEO and board member at the end of December 31, 2026. Sud's employment agreement sets a $2,600,000 base salary, a target bonus of two times salary, and equity awards including a $10,000,000 sign-on grant, which shareholders can track in the filing.
Anjali Sud, 43, becomes CEO effective January 1, 2027, and will remain on the Board
Sud's employment agreement sets a $2,600,000 base salary and a target bonus equal to two times base salary
Sud's package includes a $10,000,000 sign-on RSU grant and $4,500,000 in time-based and $4,500,000 in performance-based RSUs
Witz will serve as an advisory consultant from January 1, 2027 through December 31, 2027 at $175,000 per month
Former CEO Dr. Andrew Regan, writing on behalf of Corvus Capital Limited, told the Board in a November 5, 2026 letter that Corvus intends to make a non-binding proposal to acquire all outstanding common stock at $2.00 per share, a 96.3% premium on a post-split basis to the November 4, 2026 closing price, absent a Board proposal. The Board intends to form a special committee of independent directors with full authority over the proposal, but the committee has received no definitive terms and has made no decision, and there is no assurance any transaction will result.
Letter dated November 5, 2026, from Dr. Andrew Regan, former CEO, as a significant stockholder, on behalf of Corvus Capital Limited
Proposed price of $2.00 per share, a 96.3% premium to the November 4, 2026 closing price, on a post-split basis
Board intends to form a special committee of independent directors with full authority to consider and vote on the proposal
No definitive terms received and no decision made; the company does not commit to provide updates
In the week of November 2 to November 8, 2026, Strategy reported $283.8 million in net proceeds from sales of its MSTR Class A common stock under its at-the-market program, and used $81.9 million of those proceeds to buy 1,036 bitcoin. It also spent $188.3 million repurchasing STRC preferred stock and held $146.2 million in USD Cash as of November 8.
MSTR common stock sales: 2,051,348 shares, $283.8 million net proceeds, with $18.3 billion still available for issuance
Bitcoin: 1,036 bitcoin bought for $81.9 million; aggregate holdings reached 850,364 bitcoin at an average purchase price of $75,456
STRC preferred repurchases: 1,887,464 shares for $188.3 million; $560.3 million remains under the preferred repurchase program
USD Reserve stood at $4.77 billion as of November 8, 2026, after $21.1 million was used for preferred dividends
Future Vision II Acquisition Corp. (FVN) received written notice on November 5, 2026, from Nasdaq confirming it has regained compliance with the minimum public holders requirement for continued listing on the Nasdaq Capital Market. Nasdaq said the matter is now closed, so the company is no longer under this listing deficiency.
Notice received November 5, 2026 from Nasdaq's Listing Qualifications Department
Compliance regained with minimum public holders requirement under Nasdaq Listing Rule 5550(a)(3)
Nasdaq stated the matter is closed; the 8-K was signed by CEO and Director Danhua Xu on November 9, 2026
Strive reported it bought 29 bitcoin between October 31 and November 6, 2026, at an average price of about $75,721 per bitcoin, including fees and expenses. Its bitcoin holdings rose from 43,124 to 43,153 over the period, while cash and cash equivalents fell by $2.8 million to $487.6 million.
Bitcoin purchased: 29 bitcoin at an average price of approximately $75,721 per bitcoin, inclusive of fees and expenses
Bitcoin held rose from 43,124 as of October 30, 2026 to 43,153 as of November 6, 2026
Cash and cash equivalents fell from $490.4 million to $487.6 million over the same period
Effective Common Shares Outstanding were unchanged at 127,331,109; SATS Stock shares rose by 33,141 to 7,036,559
Goodyear appointed Roger Wood, a current board member, as interim chief executive officer and president effective November 8, 2026, replacing Mark Stewart, who also resigned from the board. The company will search for a permanent successor while a board special committee continues a strategic review of its businesses and operations.
Wood's salary is $310,000 per month, plus a monthly restricted stock unit grant with a grant date value of $1,000,000 for up to five months or until a permanent successor is hired.
Stewart's separation is classified as a termination other than for Cause under the company's Executive Severance and Change in Control Plan.
Wood will step down as chair of the board's human capital and compensation committee and will not serve on the Human Capital and Compensation or Governance Committees while interim CEO.
Jerome Rouquet will become executive vice president and chief financial officer effective December 1, 2026, succeeding interim CFO Scott Deakin.
Soluna Holdings announced it will release its third quarter 2026 financial results on Monday, November 16, 2026, and host a conference call and webcast at 5:00 PM ET that day. The announcement gives no financial figures, so it does not by itself show the quarter's performance.
Third quarter 2026 results release date: Monday, November 16, 2026
Conference call and webcast begin at 5:00 PM ET on the same day
Replay to be available at www.solunacomputing.com/investors after the event
Azora Therapeutics appointed three new independent directors, Aida Habtezion, Paul Hastings and Thomas Soloway, effective November 3, 2026, and four directors resigned the same day, reducing the board to five members. Separately, 9,924,260 common shares were issued on conversion of Series A Preferred Stock, bringing common shares outstanding to 14,243,129 as of November 4, 2026.
Three directors appointed November 3, 2026: Aida Habtezion, M.D., Paul Hastings and Thomas Soloway; the board was reduced to five members
Four directors resigned effective November 3, 2026: J. Kermit Anderson, Cary J. Claiborne, Robertson H. Gilliland and Kevin Schuyler; Matthew Davidson was named board chair
9,924,260 common shares issued on automatic conversion of 9,924.260 Series A Preferred shares effective November 2, 2026; 3,006.341 preferred shares remain outstanding
Company has not finalized non-employee director compensation; no equity awards granted to the new directors
Atea Pharmaceuticals entered a Loan and Security Agreement with Hercules Capital on November 6, 2026, providing for senior secured term loans of up to $200.0 million, with $65.0 million drawn at closing. The loans mature on November 1, 2031, and are secured by substantially all of the company's assets, including its intellectual property, which gives shareholders a larger fixed debt obligation tied to the company's development of BEM/RZR.
Tranche 1 loan of $65.0 million was drawn on the November 6, 2026 closing date; further tranches total up to $135.0 million
Interest floats at the greater of the WSJ prime rate plus 2.35% or 9.35%, paid monthly, with interest-only payments for 48 months
Tranche 2 availability depends on completing the Phase 3 trial of BEM/RZR before a specified date in the second half of 2027
Financial covenants include a minimum cash test beginning October 1, 2027, and a performance covenant tied to FDA approval of BEM/RZR
Ocular Therapeutix's board elected Riad Sherif, M.D., as a director effective November 6, 2026, and director Seung Suh Hong gave notice of his resignation effective December 31, 2026. The filing says Hong's resignation is not due to any disagreement with the board or management, and Sherif receives the same non-employee director compensation as other outside directors.
Riad Sherif, M.D., 58, elected to the board effective November 6, 2026 as a Class I director, serving until the 2027 annual meeting
Sherif received an option for 88,000 shares at $6.60 per share and a restricted stock unit award for 28,000 shares, vesting annually over three years
Sherif is CEO and a board member of Oculis Holding AG; he previously held roles at Novartis and Alcon
Seung Suh Hong, Ph.D., resigns from the board effective December 31, 2026
Silexion Therapeutics, a Cayman Islands company trading on Nasdaq as SLXN, announced a 1-for-24 reverse share split of its ordinary shares. Split-adjusted trading begins at market open on November 11, 2026, and the company says the split is intended to help it regain compliance with Nasdaq's minimum bid price requirement.
Every 24 ordinary shares will be automatically combined into one share, with the par value increasing from $0.135 to $3.24 per share
Split-adjusted trading begins on the Nasdaq Capital Market at market open on November 11, 2026, under the existing ticker SLXN, with the split effective after market close on November 10, 2026
No fractional shares will be issued; DTC participants entitled to fractions will receive a rounded-up whole share, and shareholders need not take action
FACT II Acquisition Corp., a Cayman Islands blank-check company, is asking shareholders to approve extending its deadline to complete an initial business combination from November 27, 2026 to November 25, 2027, at an extraordinary general meeting set for November 17, 2026. The company also disclosed that it and its sponsor intend to seek non-redemption agreements, under which investors would agree not to redeem shares in exchange for future share transfers, which could increase the cash left in the trust account; the company states no assurance that such incentives will be offered.
Shareholder meeting scheduled for November 17, 2026, at 10:00 a.m. Eastern Time; the deadline to submit shares for redemption is 5:00 p.m. Eastern Time on November 13, 2026.
Estimated redemption price was approximately $10.81 per share as of November 6, 2026, based on about $189,186,398.23 in the trust account.
Sponsor HoldCo anticipates transferring Class B ordinary shares to non-redeeming investors, with terms set in the Non-Redemption Agreements (Exhibit 10.1).
Brady Corporation said two new directors, Scott J. Robinson and Kenneth J. Spangler, joined its Board effective November 9, 2026, and that director Patrick W. Allender will retire and not stand for re-election at the upcoming Annual Shareholders' Meeting. Robinson joins the Audit Committee and Spangler joins the Technology Committee, and each will receive a $160,000 stock award. The filing is a board composition change and does not report financial results or guidance.
Scott J. Robinson and Kenneth J. Spangler join the Board effective November 9, 2026; both were elected November 6, 2026.
Patrick W. Allender, who served 19 years on the Board, notified the Board on November 6, 2026 of his retirement.
Robinson joins the Audit Committee and Spangler joins the Technology Committee.
Each new director will receive a $160,000 fair value award of unrestricted Class A Nonvoting Common Stock, dated November 9, 2026.
News Corp filed two daily buy-back notices with the Australian Securities Exchange covering open-market repurchases of its Class A and Class B common stock on November 6, 2026, under its program authorized at up to $1 billion. The filing states that $574,365,655 has been paid under the program to date, so the company continues to reduce its share count, which matters to shareholders because repurchases can support per-share measures.
Class A: 28,539 shares bought on November 6, 2026 for $754,208.71; 14,191,858 shares for $377,171,863.40 before that day.
Class B: 12,422 shares bought on November 6, 2026 for $362,018.07; 6,548,856 shares for $196,077,565.27 before that day.
The filing says $574,365,655 has been spent under the $1 billion program authorized July 15, 2025.
Reported price ranges: Class A $22.20 (February 9, 2026) to $31.58 (August 27, 2026); Class B $25.49 (February 13, 2026) to $35.69 (August 27, 2026).
Precision BioSciences said it expects its November 5, 2026 share offering, along with existing cash, its at-the-market facility and continued cost discipline, to fund operations into the fourth quarter of 2029. The company projects it is sufficiently capitalized to fund its PBGENE-HBV and PBGENE-DMD clinical programs through key next-stage inflection points. The filing does not state the net proceeds amount.
Offering of 10,235,077 common shares at $7.75 per share, under an underwriting agreement dated November 5, 2026
Pre-funded warrants for up to 5,893,964 shares offered in lieu of common stock to certain investors, at $7.749995 per warrant
Expected cash runway into the fourth quarter of 2029, covering PBGENE-HBV and PBGENE-DMD programs
ProKidney reported cash and marketable securities of $141.9 million as of September 30, 2026, in a filing that also furnished an updated investor presentation. The filing contains no revenue, net loss or per-share figures, so the cash balance and the company's stated runway are the main financial disclosures for shareholders.
Cash and marketable securities were $141.9 million as of September 30, 2026.
The updated investor presentation says current cash is expected to support operating plans into mid-2027.
The presentation lists the Phase 3 PROACT 1 topline readout for Q2 2027 and a BLA submission for Q1 2028.
The filing does not include revenue, net income or loss, or earnings per share.
Walker & Dunlop published a November 9, 2026 investor presentation on its Investor Relations website, furnished as Exhibit 99.1 under Regulation FD and not deemed filed. The deck cites a $146.6 billion servicing portfolio as of September 30, 2026, a $62 million remaining share buyback authorization, and net debt to adjusted EBITDA of 2.8x, giving shareholders a snapshot of the company's capital position. The 8-K text itself reports no new quarterly financial results.
Presentation published November 9, 2026 and dated the same day as Exhibit 99.1
Servicing portfolio of $146.6 billion at September 30, 2026, a 2% increase year to date
$62 million share buyback authorization remaining and net debt to adjusted EBITDA of 2.8x (trailing twelve months)
Presentation cites about $20 million of run-rate fixed expense reduction starting in Q2 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.